MedTrace Logo

Magnetic Nanoparticles System in Acute Coronary Syndrome

NCT02226523 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 455

Last updated 2024-07-26

No results posted yet for this study

Summary

To improve the sensitivity and specificity of immunoassay, the developing trends are to lower the detection threshold and to minimize the cross reaction. A new assay technology called immunomagnetic reduction (IMR) has been developed for rapid and on-site assay with small volume of sample. Rapid diagnosis of acute coronary syndrome (ACS) is a clinical and operational priority in busy emergency departments (ED), early and correct diagnosis is important. Cardiac enzymes (including CPK/CK-MB, troponins, myoglobulin) and electrocardiography (ECG) in combination with the medical history and physical examination are at present the diagnostic cornerstones. Novel biomarkers that rise earlier, have good diagnosis accuracy and have additional prognostic information are highly needed. The combination of multiple biomarker assays (markers of myocardial injury, inflammation/plaque ruptures or heart failure with different mechanism) may increase clinical sensitivity and improve early risk stratification. The present study, a rapid IMR assay with multiple biomarkers is proposed and we will examine the performance of this new investigational IMR assays, comparison with current commercial assays.

Conditions

  • Acute Coronary Syndrome

Sponsors & Collaborators

  • National Taiwan University Hospital

    collaborator OTHER

  • Far Eastern Memorial Hospital

    lead OTHER

Principal Investigators

  • Yen-Wen Wu, MD, PhD · Far Eastern Memorial Hospital

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02226523 on ClinicalTrials.gov